Futu News reported on April 27 that$MABWELL-B (02493.HK)$The Grey Market currently shows a 6.01% increase, trading at HKD 29.3 per share. Each lot consists of 200 shares, and excluding handling fees, a profit of HKD 332 can be made per lot.
Source of Market Data: Futu Securities
Company Overview
The company is a Chinese pharmaceutical enterprise renowned for its innovative capabilities in drug research and development as well as its end-to-end operational capacity from drug discovery to commercialized sales. Its pipeline focuses on oncology and age-related diseases, which pose significant global health risks and represent unmet clinical needs.
The company has established a competitive pipeline product portfolio, including four marketed products and ten drug candidates (one at the NDA stage, eight in clinical stages, and one in preclinical stages), with a focus on oncology and age-related diseases such as immunology, ophthalmology, and orthopedics. The core product, 9MW2821 (BFv, an ADC targeting Nectin-4), is one of the company’s ADC technology products, showcasing its expertise in this field.
Financial Highlights
In 2024 and 2025, the company recorded revenues of RMB 199.6 million and RMB 659.0 million, respectively; its R&D costs increased from RMB 782.9 million in 2024 to RMB 977.0 million in 2025; and its gross profit grew from RMB 169.2 million in 2024 to RMB 596.4 million in 2025.
Futu's grey market platform is stable and supports rapid order placement with market orders. Over 850,000 people have used Futu for subscribing to new shares, gaining an edge in the grey market, and executing trades faster than others.Come and experience it >>
Editor/Deng